Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

作者：R. Kreitman, P. Moreau, F. Ravandi, M. Hutchings, A. Gazzah, A. Michallet, Z. Wainberg, A. Stein, S. Dietrich, M. D. de Jonge, W. Willenbacher, J. De Grève, E. Arons, P. Ilankumaran, P. Burgess, E. Gasal, V. Subbiah · 发表于：Blood · 年份：2022 · DOI：10.1182/blood.2021013658 · 被引用次数：44 · 研究领域：Medicine

Key Points • Dabrafenib + trametinib showed durable responses with a manageable safety profile in patients with relapsed/refractory BRAF V600E–mutant HCL.• This combination should be considered a meaningful therapeutic option for patients with relapsed/refractory BRAF V600E–mutant HCL.